Answers are grounded in this paper and cite their sources.
Randomized trial assesses dengue burden in children, highlighting geographic differences and the need for adaptive strategies.
Data from the placebo arm of DEN-301, a phase 3 trial of the TAK-003 dengue vaccine, were evaluated in this secondary post hoc analysis to assess dengue burden. Participants were aged 4–16 years from Asia Pacific and Latin America. The primary endpoint was efficacy of TAK-003 against virologically confirmed dengue (VCD). Hospitalized VCD was a secondary endpoint. Active surveillance captured both hospitalized and non-hospitalized cases. Among 6,687 placebo participants (30,620.6 person-years (p-y)), 9,698 febrile illnesses (incidence rate (IR) 31.7 per 100 p-y) occurred; 5.8% ( n = 560) were dengue. Most were DENV-1 (41.1%) or DENV-2 (34.5%). Dengue incidence differed between Asia Pacific (IR 2.7 per 100 p-y) and Latin America (IR 1.2 per 100 p-y). A total of 19 participants had dengue haemorrhagic fever or severe dengue. Of the VCD cases, 25.4% (142/560) were hospitalized. Here we highlight geographic, age-specific and temporal differences in dengue disease, underscoring the need for adaptive public health strategies to effectively control the disease (ClinicalTrials.gov identifier: NCT02747927 ).
No takes yet. Share an insight, caveat, or question.
Kastner et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: